Intravascular Targets for Molecular Contrast-Enhanced Ultrasound Imaging by Moestue, Siver Andreas et al.
Int. J. Mol. Sci. 2012, 13, 6679-6697; doi:10.3390/ijms13066679 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Review 
Intravascular Targets for Molecular Contrast-Enhanced 
Ultrasound Imaging 
Siver A. Moestue 1,*, Ingrid S. Gribbestad 1 and Rune Hansen 2 
1 MI Lab, Department of Circulation and Medical Imaging, Norwegian University of Science and 
Technology (NTNU), Trondheim N-7006, Norway; E-Mail: ingrid.s.gribbestad@ntnu.no 
2 Department of Medical Technology, SINTEF Technology and Society, Trondheim N-7491, 
Norway; E-Mail: rune.hansen@sintef.no 
* Author to whom correspondence should be addressed; E-Mail: siver.a.moestue@ntnu.no;  
Tel.: +47-911-111-74; Fax: +47-735-513-50. 
Received: 19 April 2012; in revised form: 21 May 2012 / Accepted: 22 May 2012 /  
Published: 1 June 2012 
 
Abstract: Molecular targeting of contrast agents for ultrasound imaging is emerging as a 
new medical imaging modality. It combines advances in ultrasound technology with 
principles of molecular imaging, thereby allowing non-invasive assessment of biological 
processes in vivo. Preclinical studies have shown that microbubbles, which provide 
contrast during ultrasound imaging, can be targeted to specific molecular markers. These 
microbubbles accumulate in tissue with target (over) expression, thereby significantly 
increasing the ultrasound signal. This concept offers safe and low-cost imaging with high 
spatial resolution and sensitivity. It is therefore considered to have great potential in cancer 
imaging, and early-phase clinical trials are ongoing. In this review, we summarize the 
current literature on targets that have been successfully imaged in preclinical models using 
molecularly targeted ultrasound contrast agents. Based on preclinical experience, we 
discuss the potential clinical utility of targeted microbubbles. 
Keywords: ultrasound imaging; targeted contrast agents; angiogenesis; molecular imaging; 
microbubbles; cancer 
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1. Introduction 
Compared with other medical imaging modalities, ultrasound imaging has several advantages.  
It does not involve radiation, has high spatial resolution and is generally considered cheap, safe and 
widely available. The introduction of gas-filled microbubbles as contrast agents for ultrasound imaging 
has further improved the performance and increased the versatility of ultrasound imaging. 
In in vivo molecular imaging, targeted probes are used for non-invasive imaging of molecules 
overexpressed in disease. This principle can be used also in ultrasound imaging. Conjugating 
microbubbles with specific ligands allows non-invasive imaging of target expression with high 
sensitivity. However, microbubbles are confined to the intravascular compartment. Their use as 
molecular contrast agents is therefore restricted to diseases which are directly or indirectly associated 
with altered phenotype of cells present in the intravascular compartment. Nevertheless, several 
interesting indications for targeted microbubbles exist. For example in atherosclerosis, subendothelial 
lesions cause inflammatory changes in the endothelium. In solid tumors, the cancer cells stimulate the 
endothelium and induce neoangiogenesis, leading to upregulation of several molecules on the 
endothelial surface. 
Over the last decade, molecular contrast-enhanced ultrasound imaging has been established as a 
useful technique for imaging intravascular angiogenic markers in cancer. Proof-of-concept studies in 
preclinical models have repeatedly demonstrated that retention of targeted microbubbles, and thus the 
signal intensity of the ultrasound images, reflects the expression of target biomarkers. Here, we 
summarize the findings from preclinical studies of molecular ultrasound contrast agents with the 
intention to describe the potential clinical utility of these agents in ultrasound imaging of  
tumor vasculature. 
2. Ultrasound Contrast Agents 
Contrast agents for ultrasound consist of micrometer-sized gas bubbles stabilized by a thin 
encapsulating shell made of lipid, albumin or biocompatible polymers which are intravenously 
administered. Such microbubbles can undergo strong oscillations when exposed to an ultrasound 
beam. This leads to strong back-scattering of waves enabling detection of the microbubbles and 
thereby assessment of micro-circulation and perfusion. In the early eighties, Feinstein [1,2] was one of 
the first to develop air microbubbles encapsulated in protective shells small enough for transpulmonary 
passage. About 10 years later, the first generation of commercial contrast agents (such as Echovist®, 
Albunex®, Levovist®) was available. A few microbubble agents with mean diameter of 1–4 microns 
(Definity®, Optison®) are currently the only FDA approved contrast agents for ultrasound. The flow 
pattern of conventional non-targeted microbubbles is typically similar to erythrocytes within the 
circulation system [3]. Targeting can be achieved through conjugation of disease-specific ligands for 
the target molecule to the microbubble shell. Molecular imaging with ultrasound relies on detection of 
targeted microbubbles. Because of the large size of the microbubble, it is only possible to target 
molecules occurring in plasma or on the surface of the endothelial cells. Seconds after an intravenous 
bolus administration, contrast agent inflow provides real-time information of blood flow patterns 
within a region of interest. A few minutes later, imaging of microbubbles attached to molecular targets 
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may be performed and 5–15 minutes after administration most of the free circulating microbubbles are 
typically cleared from the bloodstream (Figure 1). Differentiating targeted bubbles retained in diseased 
tissue from free circulating bubbles can be done either by waiting until all circulating bubbles are 
cleared from the bloodstream or by using a subtraction technique comparing the back-scattered signal 
before and after a high amplitude destruction pulse has been applied. Free flowing bubbles and bubbles 
bound to molecular targets at the endothelial cells will potentially have different resonance frequencies 
due to different oscillation conditions. It is then, for example with the use of dual frequency band detection 
techniques, possible to differentiate the received echoes from unbound and retained bubbles [4]. 
Figure 1. The principle of molecular contrast-enhanced ultrasound. Microbubbles 
conjugated to specific ligands are injected into the circulation. In healthy capillaries, the 
expression of target receptors is low. Consequently, the microbubbles do not bind to the 
target but remain in circulation. In an angiogenic blood vessel, the activated endothelium 
target receptor is overexpressed. The microbubbles bind to the receptors and accumulate in 
the vessel. Despite a loss of basal membrane integrity in the diseased vessel, the 
microbubbles are too large to extravasate and remain in the intravascular compartment. 
 
2.1. Advantages and Disadvantages of Ultrasound Compared to Other Modalities 
Ultrasound molecular imaging offers several advantages and some limitations compared to other 
imaging modalities. Low equipment cost, mobility of equipment and rapid execution of imaging 
protocols are important advantages of ultrasound. Spatial resolution is comparable to magnetic 
resonance imaging (MRI) for imaging of relatively small objects close to the transducer (e.g., prostate, 
breast, and thyroid) [5]. Contrast agent sensitivity is excellent with ultrasound where individual 
microbubbles can be detected [6]. For MRI, contrast agent sensitivity is a limitation. Computerized 
tomography (CT), single photon emission computerized tomography (SPECT) and positron emission 
tomography (PET) have good sensitivity but all of these modalities utilize ionizing radiation and 
SPECT and PET also suffers from inferior spatial resolution. Another important advantage with 
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ultrasound is the rapid clearance of unbound microbubbles and the possibility to destroy circulating 
and retained microbubbles within a desired region of interest [7,8]. This allows for repeated 
examinations and for imaging of multiple molecular targets in the same subject. Finally, ultrasound 
boasts excellent temporal resolution and allows real-time image evaluation. Regarding disadvantages, 
a whole-body scan is not feasible with ultrasound and some organs (e.g., lungs and brain without 
performing a craniotomy) are difficult to examine by ultrasound. When imaging large organs or 
objects far from the transducer, spatial resolution is typically inferior to MRI and CT. Ultrasound has 
until recently mainly been a two-dimensional imaging modality but real-time three-dimensional 
imaging is now starting to be implemented on high-end scanners. In Figure 2, representative images 
obtained using αvβ3-targeted contrast agents are presented, illustrating differences in sensitivity and 
spatial resolution between different imaging modalities. 
Figure 2. Molecular imaging of the αvβ3 integrin. The advantages and disadvantages of 
different medical imaging modalities are demonstrated in representative images from 
tumor-bearing animals. A, B, C and D show single photon emission computerized 
tomography (SPECT), positron emission tomography (PET), optical imaging and magnetic 
resonance imaging (MRI), respectively. E and F shows a xenograft tumor after injection of 
microbubbles conjugated with ariginine-glycine-aspartic acid (RGD) or a scrambled 
control peptide, respectively. G shows the presence of single microbubbles after injection 
of αvβ3-targeted microbubbles. Reproduced with permission from [9–14]. 
 
The major limitation of molecular contrast-enhanced ultrasound imaging is that microbubbles are 
restricted to the vascular lumen, and only targets in this compartment can be imaged. 
2.2. Requirements for Intravascular Targets in Ultrasound Imaging 
Intravascular targets for contrast-enhanced ultrasound imaging must meet the same requirements as 
other targets for molecular contrast agents. First, the target should be extracellular. These targets  
in general are easier to image than intracellular targets, as internalization of contrast agent is not 
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required [15]. Second, the target should be expressed in high numbers. By pure stoichiometry, this 
allows binding of large amounts of contrast agent, which enhances the sensitivity of disease detection. 
Third, the expression of the target must be altered significantly in order to distinguish between the 
normal and diseased state of the tissue, at a clinically relevant time point. The magnitude of the altered 
expression in diseased tissue represents the maximum achievable target-to-background ratio that can 
be achieved during imaging. The unspecific binding of the contrast agent should be as low as possible 
in order to reduce background signal. This is typically tested by comparison of targeted microbubbles 
and microbubbles with isotype (non-binding) control ligand. Combining an intravascular target with 
low native abundance and high upregulation in disease with a microbubble conjugated to a highly specific 
ligand is therefore a requirement for successful differentiation between lesions and normal tissue. 
Antibodies usually have high binding specificity and are frequently used in target validation or 
proof-of-concept studies. However, due to manufacturing issues and the risk of immunological adverse 
effects, antibodies are less clinically desirable [16]. Therefore, the use of low-molecular ligands, such 
as small peptides, is advantageous. Such ligands are generally easier to manipulate and conjugate with 
the reporter part of the contrast agent. The binding kinetics may be improved compared to antibodies, 
and such ligands may be incorporated in the microbubble shell instead of being conjugated using the 
biotin-streptavidin linker [17,18]. Ideally, the ligand should not exert any pharmacological effect, as 
this increases the risk of adverse side effects. The binding of ligand to the target should be specific, 
rapid and strong. The shear forces may rapidly move the contrast agent away from the target if it does 
not bind with sufficient strength within a short period of time. The effect of shear forces on 
microbubble binding is less in capillaries, where the blood flow is much lower. 
The intravascular confinement of microbubbles represents both a limitation and an advantage.  
As the bubbles do not extravasate, they can only attach to targets expressed on the luminal side of 
endothelial cells. This limits the number of possible targets. However, this also allows imaging of the 
vascular pathology without any interference from extravascular tissue. The selectivity for vascular 
endothelium may be advantageous in cases where the target receptor is expressed both in the vascular 
compartment and in the surrounding tissues, or if extensive unspecific binding of ligand is observed in 
the surrounding tissue. 
3. Molecular Ultrasound Imaging of Cancer 
Cancer can be defined as diseases where cells divide in an uncontrolled manner and are able to 
invade other tissues. Solid tumors depend on formation of new blood vessels in order to grow beyond a 
size of 1–2 mm [19,20]. As changes in vascular architecture and function in the affected tissue is an 
integrated part of the pathology, assessment of blood vessels and their function is a useful approach in 
imaging of cancer [21,22]. The progression to invasive and eventually metastatic cancer depends on 
angiogenesis, and imaging of this process is an important approach for early detection and 
characterization of cancer. 
Development of angiogenic capability is typically acquired at a relatively late time point during 
tumorigenesis [19]. To explain this, the “angiogenic switch” model has been developed [23]. The 
relative balance between inhibitors and activators of angiogenesis is in general in favor of vascular 
quiescence. At some point in tumor development, loss of inhibitors or increased amount of activators 
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(for example due to cumulative mutations in oncogenic signaling pathways) turns the balance in favor 
of angiogenesis, ultimately tipping it in favor of new blood vessel growth. This understanding has led 
to the development of antiangiogenic drugs, which impair the vascularisation of tumors. Although this 
in theory should deprive tumors of oxygen and nutrients, the clinical efficacy of antiangiogenic drugs 
has turned out to be smaller than expected [24]. 
The tumor vasculature has a different morphology and biology than mature, quiescent vessels [25]. 
It is tortuous and leaky, and the blood flow is often compromised. The phenotype of the endothelial 
cells is changed in response to the angiogenic activator molecules, and they overexpress a number of 
proteins compared to normal endothelium. These proteins are potential targets for drugs or contrast 
agents. Findings from in vivo studies of ultrasound contrast agents targeting angiogenesis are 
summarized in Table 1. 
3.1. VEGFR2 
The most important molecule for control of the angiogenic process is the vascular endothelial 
growth factor A (VEGFA), which is produced by cancer cells as a response to hypoxia. VEGFA binds 
to the VEGF-receptor 2 (VEGFR2) on endothelial cells, activates the cells and induces vascular 
sprouting. Upregulation of VEGFR2 is observed both in animal models of cancer and in humans, and 
its expression is a prognostic marker in a variety of malignancies. In gliomas, the expression of 
VEGFR2 is 3–5 fold higher in tumor vasculature than in normal vasculature [39,40]. Based on the 
physiological and pathophysiological properties of VEGFR2 it is considered an attractive target for 
imaging agents for use in all modalities. However, as the number of endothelial cells is far less than 
the number of tumor cells, high sensitivity is a prerequisite for imaging VEGF receptors. It has 
repeatedly been demonstrated that molecular contrast-enhanced ultrasound can be used to image 
VEGFR expression [31,41,42]. The most widely used approach for targeting microbubbles to 
VEGFR2 is by conjugating anti-VEGFR2 antibodies to the shell. The performance of such 
microbubbles is similar to that observed using heterodimer-based peptide ligands, with 3 to 4-fold 
increase in signal intensity in angiosarcoma and glioma models [31]. Although the targeting efficacy 
may differ, preclinical studies using different VEGFR2-targeting ligands have demonstrated the 
superiority of targeted versus non-targeted microbubbles and confirmed that VEGFR is a valid target 
in angiogenesis imaging. The target-to-background ratio achieved using ultrasound imaging is similar 
to that achieved using SPECT and PET agents [43,44]. However, the achieved target-to-background 
ratio depends strongly on the VEGFR2 expression and the vascular architecture of the  
experimental model. 
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Table 1. Summary of studies using targeted microbubbles (MBs) to assess tumor angiogenesis. 
Target Ligand Model System Tumor Contrast Enhancement Compared 
to Non-Targeted Control MBs 1 
Other Findings Reference 
VEGFR2/KDR 
Heterodimeric 
peptide  
(BR55) 
Mouse  
Colon carcinoma xenograft 
LS174T 
3-fold  
Video intensity corresponds to MVD and VEGFR2 expression, allowing 
monitoring of antiangiogenic therapy 
[26] 
VEGFR2 
Heterodimeric 
peptide 
(BR55) 
Rat 
Mammary carcinoma 
13762 MAT B III 
NA 
The binding specificity of microbubbles with heterodimeric peptide ligand 
was similar to that of microbubbles with anti-VEGFR2 antibodies 
[18] 
VEGFR2 
Heterodimeric 
peptide 
(BR55) 
Mouse 
Breast cancer xenograft 
MCF-7/MDA-MB-231 
NA 
2-fold difference in VEGFR2 expression between tumor models reflected 
in video intensity 
[27] 
VEGFR2 
Heterodimeric 
peptide 
(BR55) 
Rat 
Prostate adenocarcinoma 
G Dunning R-3327 
NA 
20-fold difference in signal intensity between prostate cancer and normal 
tissue. Binding similar to that of antibody-coated bubbles  
[28] 
VEGFR2 Antibody 
Mouse 
Breast cancer xenograft 
NR67 
2.5-fold  
Retention of VEGFR2-targeting bubbles correlate to VEGFR2 expression 
but not vascularity 
[29] 
VEGFR2 Antibody 
Mouse 
Pancreatic cancer xenograft 
MiaPaCa2/Pan02 
1.5-fold  
Reduced endothelial expression of VEGFR after treatment with 
gemcitabine  
[30] 
VEGFR2 Antibody 
Mouse/Rat 
Angiosarcoma (SVR) 
Glioma (C6) 
3-5 fold  
Unspecific control MBs had significantly higher video intensity than 
unlabeled MBs (10-fold) 
[31] 
VEGFR2 Antibody 
Mouse 
Squamous cell carcinoma 
HaCaT-ras-A-5RT3 
7.5-fold  
Reduced microbubble retention after matrix metalloproteinase inhibition. 
No significant difference between VEGFR2- and αvβ3-targeted 
microbubbles 
[32] 
αvβ3 Echistatin 
Rat 
Glioma xenograft 
U87MG 
3-fold  Spatial variation in signal intensity corresponded to integrin expression [33] 
αvβ3 Knottin 
Mouse  
Ovarian cancer xenograft 
SK-OV-3 
3-fold  
Knottin-decorated MBs outperformed MBs conjugated with RGD or 
antibodies and had a 12-fold tumor-muscle ratio  
[14] 
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Table 1. Cont. 
αvβ3 Cyclic RGD peptide 
Mouse  
Breast cancer xenograft 
Met-1 
8-fold   [9] 
αvβ3 RGD 
Mouse 
Squamous cell carcinoma 
HaCaT-ras-A-5RT3 
5-fold   [32] 
Endoglin (CD105) Antibody 
Mouse 
Pancreatic cancer xenograft 
MiaPaCa2 
1.5-fold   [30] 
VEGFR2 
αvβ3 
Endoglin (CD105) 
Antibodies 
Mouse  
Subcutaneous xenografts 
MDA-MB361 (breast) 
SKOV-3 (ovarian) 
MiaPaCa2 (pancreatic) 
NA 
Microbubbles targeting endoglin had up to 3-fold higher video intensity 
than microbubbles targeting VEGFR2 or αvβ3. In pancreatic tumors, 
microbubbles targeting αvβ3 had the highest video intensity 
[34] 
Unknown RRL 
Mouse  
Prostate cancer xenograft  
PC-3 
3-fold  Spatial variation in signal intensity corresponded to vascular density [35] 
ICAM-1 
αvβ3 Antibody 
Rat 
Prostate cancer xenograft 
AT-1 
3-fold  Approximately 1.5-fold higher video intensity than RGD-labeled MBs [36] 
VEGFR2 + αvβ3 2 x antibody 
Mouse  
Ovarian cancer xenograft 
SK-OV-3 
4-fold (VEGFR2) 
3-fold (αvβ3) 
6-fold (VEGFR2 + αvβ3) 
Dual-targeted microbubbles outperformed microbubbles with only one 
ligand 
[37] 
VEGFR2 + αvβ3 + 
ICAM1 
3 x antibody 
Mouse 
MDA-MB-231 
NA 
Triple-targeted microbubbles had 1.6-fold higher signal intensity than the 
additive intensity of all three single-targeted microbubbles, and 
approximately 5-fold higher VI than any of the single-targeted 
microbubbles alone 
[38] 
1 The figures are not directly comparable, as different disease models express varying levels of angiogenic markers, and the imaging parameters and time points are varying. Data are either obtained from 
quantitative tabular data or visual interpretation of graphical representation of imaging performance in the reviewed papers. 
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In a recent publication, Pysz et al. studied the target specificity of the VEGFR2-targeting 
microbubble BR55 [26]. This contrast agent is conjugated with a lipopeptide, which is less 
immunogenic than streptavidin-linked antibodies, improving its clinical translatability. In colon cancer 
xenografts, more than 3-fold higher signal intensity for BR55 compared to non-targeted control 
microbubbles was observed. The VEGFR2-targeting microbubbles provided 20-fold higher signal 
intensity in the xenograft tumors compared to muscle tissue, due to combined effects of increased 
vascularity and specific targeting of VEGFR2. In a rat prostate cancer model, the same microbubbles 
had significantly better imaging performance, and a much longer residence time in the tumor tissue, 
than non-targeted microbubbles [28]. In two different breast cancer xenografts, more than 2.5-fold 
higher signal intensity was observed in a highly vascularised, aggressive model (MDA-MB-231) 
compared to a poorly vascularised model (MCF-7) using BR55 [27]. Based on preclinical findings, the 
BR55 microbubble has entered clinical trials. An early report in 12 prostate cancer patients indicated 
that this VEGFR2-targeted microbubble improved prostate cancer detection and localization [45]. 
3.2. Integrins 
Integrins are a family of cell surface receptors whose primary ligands are extracellular matrix 
proteins. A full description of integrin biology in cancer is beyond the scope of this report, but has 
recently been reviewed by Avraamides et al. [46]. Unlike quiescent endothelium, tumor-associated 
endothelium (and sites of wound healing and inflammation) express the integrin receptor αvβ3 [47].  
It is believed that the activation of integrin receptors stimulate synthesis of proteolytic enzymes such 
as matrix metalloproteinases, which may degrade the surrounding extracellular matrix components and 
create space for formation of a new vessel [48]. In addition, integrin receptors play a role in adhesion 
of endothelial cells to each other and the exracellular matrix during angiogenesis. 
Interestingly, expression of αvβ3 occurs at a later stage in angiogenesis than VEGFR [25]. This may 
be relevant when considering VEGFR2 and αvβ3 as targets for intravascular contrast agents. These two 
targets represent cells in different stages of angiogenesis. Although both targets may be expressed at 
the same time in a tumor, the number of cells expressing each target may vary in different stages of 
tumor progression. Targeting the αvβ3 receptor has been widely used approach in the development of 
targeted contrast agents. This is in part due to its biological properties, but also to the fact that the 
ariginine-glycine-aspartic acid (RGD) amino acid sequence is a well-defined and versatile ligand for 
this receptor. Cyclic peptide sequences have been found to have greater affinity to the αvβ3 receptor 
than linear variants [49]. 
The first preclinical studies of microbubbles targeting the αvβ3-receptor were reported by  
Leong-Poi et al. [50]. Here, microbubbles conjugated to anti-αv antibodies or echistatin showed 
selective retention in FGF2-induced muscular angiogenesis. It was demonstrated that the retention was 
caused by attachment to endothelial cells rather than size-dependent entrapment. Later studies 
confirmed the signal intensity of microbubbles conjugated to echistatin correlated both to integrin 
expression and tumor blood volume in a rat xenograft model of glioma, demonstrating the potential of 
noninvasive imaging of tumor angiogenesis [33]. In this study, tumor growth was associated with 
increased blood volume and increased signal intensity in the ultrasound images, in particular in the 
peripheral regions of the tumors. This demonstrates how molecular contrast-enhanced ultrasound can 
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be used to study both spatial variation in tumor angiogenesis and changes in vascularity over time. 
Another approach for targeting αvβ3 overexpression in tumor vasculature is disulfide-constrained 
cystin knots (knottins). These small peptides have been shown to bind αvβ3 with low nanomolar 
affinity. Direct comparison in mouse xenograft models indicated that knottin-based and RGD-based 
microbubbles have higher target-to-background ratio than anti-αvβ3 antibody-based microbubbles [14]. 
More recently, it has been reported that microbubbles conjugated to a cyclic RGD ligand has high 
affinity for tumor vasculature in vivo [9]. For clinical translation, the use of RGD-based ligands is 
more desirable than anti-αvβ3-antibodies. 
3.3. Endoglin 
Another intravascular target for imaging of angiogenesis is endoglin (CD105). This is a member of 
the TGF-β family of receptors, which is required for endothelial cell proliferation. Overexpression of 
endoglin is associated with poor prognosis in several cancers [51]. Interestingly, CD105 is selectively 
expressed on angiogenic endothelial cells at significantly higher levels (up to 3 × 106 copies per cell) 
than other angiogenesis-related targets such as the VEGFRs (<0.2 × 106 copies per cell) [52].  
Anti-endoglin antibodies have been conjugated to microbubbles for contrast-enhanced ultrasound 
imaging. Initial studies demonstrated affinity for endothelial cells in vitro [53]. These studies were 
followed up by studies in mice carrying pancreatic cancer xenografts, demonstrating approximately 
10-fold higher signal intensity in tumor tissue than surrounding tissue [30]. Endoglin-targeting and 
VEGFR2-targeting microbubbles showed comparable signal intensities which might be due to similar 
marker expression levels in the tumors. 
3.4. Prostate-Specific Membrane Antigen 
Prostate-specific membrane antigen (PSMA) is predominantly localized to the epithelial cells of the 
prostate gland, but its function is not fully understood. It is upregulated several-fold in high-grade 
prostate cancers [54]. Interestingly, PSMA is also upregulated on the surface of tumor endothelium, 
not only in prostate cancer but in other cancers as well [55]. It is therefore a potential target for 
ultrasound contrast agents. Antibodies targeting the extracellular domain of PSMA have been 
developed, and when linked to PET nuclides these show high tumor-to-background ratio both in preclinical 
and clinical studies [56]. More recently, glutamate-urea-lysine analogues have been developed as 
inhibitors of PSMA. These peptide ligands show high selectivity and high tumor-to-background ratio 
in xenograft models when used in SPECT imaging [57,58]. A recent paper has described the 
development of prototype microbubbles targeting PSMA using a glutamate-urea-lysine analogue. 
These were shown to bind to prostate cancer cells in vitro [54]. However, no in vivo studies of  
PMSA-targeting microbubbles have been reported and the potential for successful ultrasound imaging 
of vascular PSMA is therefore currently unknown. 
3.5. Inflammatory Markers 
Imaging of conditions associated with mild or chronic inflammation has been performed using 
contrast agents decorated with antibodies or other ligands to endothelial cell adhesion molecules. Since 
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cancer frequently is associated with inflammation, ultrasound contrast agents targeting these proteins 
may potentially also be of value in cancer imaging. This has been demonstrated in the case of 
Intercellular Adhesion Molecule 1 (ICAM-1), which is associated with activated endothelial cells, 
promoting the arrest of leukocytes to inflammatory foci [59]. In a subcutaneous prostate cancer model 
in rats, specific accumulation of microbubbles targeting ICAM-1 was similar to that of αvβ3 targeted 
microbubbles [36]. Although the aim of this study was to demonstrate how two different targeted 
microbubbles can report on treatment-associated changes in tumor biology in the same imaging 
session, the results also indicate that markers for vascular inflammation can be relevant in molecular 
ultrasound imaging of cancer. Using triple-targeting microbubbles, it has also been shown that 
targeting the adhesion molecule, P-selectin, further improves the binding efficacy of VEGFR- and 
αvβ3-targeted microbubbles [38]. Microbubbles targeting adhesion molecules could therefore 
potentially be useful tools for assessing the inflammatory component of solid tumors. 
4. Therapy Monitoring in Cancer Using Molecular Contrast-Enhanced Ultrasound Imaging 
The principle of personalized medicine in cancer has led to an increased need for methods that can 
detect response to treatment, including antivascular and antiangiogenic drugs. Identification of 
responders to targeted anticancer drugs will be increasingly important as more drugs reach clinical 
practice. Ultrasound imaging is a suitable modality for this purpose, since it is a non-invasive, portable 
and non-radiative modality. In addition, it can be used to assess vascular function at several levels, 
including perfusion, blood volume and the expression of endothelial vascular markers [60,61]. Several 
studies have demonstrated that targeted microbubbles can be used for non-invasive assessment of 
angiogenic markers. Korpanty et al. [30] demonstrated that accumulation of both endoglin- and 
VEGF-targeting microbubbles correlated with target expression and microvessel density (MVD) in 
pancreatic xenograft tumors. Treatment with anti-VEGF antibodies detectably reduced the binding of 
microbubbles to endothelial cells. Similar findings have been reported using the VEGFR-targeting 
BR55 microbubble in colon cancer xenografts, where both VEGFR expression, MVD and imaging 
signal was significantly reduced after anti-VEGF antibody treatment [26]. Using an αvβ3-targeted 
contrast agent, molecular ultrasound imaging has been shown to discriminate between responding and 
non-responding xenograft tumors [62]. Following bevacizumab treatment, decrease in αvβ3-expressing 
vasculature was paralleled by a relative reduction in tumor blood volume in the responding tumor 
model only. In these experiments, adhesion of targeted microbubbles was a more consistent marker for 
response to treatment than the relative blood volume. Combining several vascular parameters obtained 
in the same ultrasound examination may further improve the sensitivity and specificity, and possibly 
also allow prediction of response based on pre-treatment data [63]. 
5. Evaluation of Intravascular Biomarkers for Angiogenesis Using Targeted Microbubbles 
Detection of microbubbles in ultrasound imaging is complex, depending on both biological  
(target expression) and physical (imaging protocol, microbubble characteristics) parameters. For 
evaluation of the abovementioned intravascular markers as targets for ultrasound contrast agents, 
direct comparisons in the same disease models using the same experimental conditions can 
nevertheless be valuable. As an example, microbubbles targeting VEGFR2 and αvβ3 have been studied 
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in subcutaneous squamous cell carcinoma xenografts, where VEGFR2-targeted microbubbles were 
found to give 1.6-fold higher signal intensity [32]. Similar findings have been reported in an ovarian 
cancer xenograft model, in a study of dual VEGFR- and αvβ3-targeting microbubbles. Here, 
microbubbles targeting VEGFR alone were found to give higher signal intensity than microbubbles 
targeting αvβ3 alone. Dual-targeted microbubbles were superior to both the two single-targeted 
microbubbles [37]. However, a longitudinal study of antibody-based microbubbles targeting αvβ3, 
VEGFR2 or endoglin in xenograft models of breast, pancreatic and ovarian cancer did not show any 
difference in the performance of αvβ3 and VEGFR2-targeted microbubbles in any model at any time 
point [34]. In addition to addressing the relative imageability of three potentially useful angiogenic 
markers, this study demonstrated the importance of experimental model characterization. The signal 
intensity after administration of endoglin-targeting microbubbles decreased with tumor size, which 
may reflect both reduced endoglin expression and a relative decrease in tumor vascularity, which is a 
typical feature of experimental subcutaneous tumors. The study also demonstrated that microbubble 
retention reflect differences in target expression between different cancers. Endoglin-targeting 
microbubbles were therefore associated with higher signal intensity than αvβ3-targeting microbubbles 
in ovarian cancer xenografts, whereas this pattern was reversed in pancreatic cancer xenografts.  
This illustrates the importance of animal model characterisation and biomarker validation during 
development of targeted contrast agents. If the receptor expression in an animal model is not 
adequately described during the selection and optimization phases of development, extrapolation of the 
findings may lead to false conclusions. Finally, selection of the correct ligand has been shown to have 
great impact on the imaging performance and specificity of targeted microbubbles. This was illustrated 
by Willmann et al. in a study comparing three different ligands for the αvβ3 integrin [14]. In this study, 
knottin ligands outperformed both an RGD peptide and an anti-αvβ3-antibody. In summary, the 
findings from preclinical studies comparing microbubbles must be interpreted with caution. In most of 
the studies, direct comparison of microbubbles has not been the primary objective, and the studies 
have been designed to assess other aspects of molecular ultrasound imaging. Due to the variability in 
angiogenic biomarker expression between cancers, no superior target for molecular ultrasound imaging 
can be identified from these studies. The body of data demonstrates that microbubbles targeting 
different angiogenic markers reflect the target expression of the biological systems, a feature which 
can be of great clinical value. 
6. Considerations for Evaluating Contrast Agent Performance 
The studies reviewed in this paper show that microbubbles targeting intravascular disease markers 
consistently give several-fold higher signal intensity than isotype control microbubbles. The difference 
between targeted and control microbubbles is in the same order of magnitude for most intravascular 
targets. Microbubble retention consistently reflects the expression of the target molecule across all 
studies. The in vivo performance of molecularly targeted contrast agents should not be compared 
without taking the properties of the model systems into account. The expression of target molecules 
related to angiogenesis is known to differ between models. Even within the same model, target 
expression can vary with time due to tumor growth or disease progression. There are also several 
factors related to the microbubble that can affect the target-to-background achieved in vivo. For 
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example, the size of the microbubbles may affect the signal intensity that can be achieved. Therefore, 
it is important to compare bubbles of similar size when evaluating different target molecules [64]. 
Other important factors are the wall shear rate and the ligand density of the microbubbles. It has been 
shown that adhesion of microbubbles increase with ligand density, and comparison of different 
microbubbles must therefore take the ligand density into account [65]. For comparison of imaging 
performance, contrast agent candidates must therefore be tested in the same animal models under the 
same experimental conditions, as discussed in section 6. It is, however, becoming increasingly clear 
that microbubbles with dual or triple targeting are superior to microbubbles carrying only one ligand. 
Multiple targeting facilitates multiple bindings between the bubbles and the endothelium and increases 
the adhesion strength to the endothelium and the retention of microbubbles in the tissue (Figure 3).  
It has been shown that combined targeting of VEGFR2 and αvβ3 is advantageous compared  
to microbubbles targeting only one of these targets [37]. Furthermore, triple-targeting microbubbles  
(P-selectin, VEGFR2 and αvβ3) have been demonstrated to have even higher tumor retention  
than dual-targeting microbubbles [38]. Interestingly, sequential administration of single-, dual- and  
triple-targeted microbubbles in the same individual animals has demonstrated significant synergy 
effects of multiple targeting. Triple-targeted microbubbles gave approximately 4-fold higher video 
intensity than any single-targeted microbubble, and 40% higher signal intensity than dual-targeted 
microbubbles [38]. 
7. Summary and Outlook 
The studies summarized above demonstrate that the intravascular compartment in cancer contains 
several targets that can be imaged using contrast-enhanced ultrasound, for diagnostic or therapy 
monitoring purposes. For successful development of a targeted ultrasound particle, several aspects 
must be taken into account. Firstly, the microbubbles must be biocompatible and have physical/acoustic 
properties matching the intended use. Secondly, a relevant molecular target (or several targets) must be 
identified. Thirdly, the microbubbles must be decorated with ligands binding to this target with 
sufficient specificity and affinity, and at a sufficient density, to facilitate binding to the target in vivo. 
Finally, the prototype microbubbles must be evaluated in clinically relevant and well-characterized 
preclinical models. Most importantly, the targeted microbubbles must produce clinically relevant 
information that has incremental diagnostic value compared to other diagnostic procedures. 
Based on the research summarized in this review, no single molecular target appears to be superior 
for ultrasound imaging of cancer. In terms of clinical translation, VEGFR2-targeting microbubbles are 
in early-phase clinical trials and may be the first to reach clinical use. Dual- or triple-targeting 
microbubbles have repeatedly been shown to outperform single-ligand microbubbles. It is therefore 
possible that future research will identify combinations of ligands which optimize the imaging performance 
and allow tailoring of contrast agents for specific purposes. A multi-purpose microbubble decorated 
with ligands both for angiogenesis and inflammation is an exciting possibility, which could reduce the 
relative development cost, as the same microbubble product can be used in different indications. 
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Figure 3. The effect of dual and triple targeting of microbubbles. (A,B) shows 
accumulation of microbubbles targeting VEGFR2 or αvβ3, respectively, in a xenograft 
tumor. (C) shows the increased accumulation after injection of microbubbles targeting both 
VEGFR2 and αvβ3. Binding of triple-targeted microbubbles (P-selectin, αvβ3 and VEGFR2) 
to cells (D) and accumulation in xenografts (E) has been proven higher than the sum of 
corresponding amount of single-targeted microbubbles. Reproduced with permission  
from [37,38]. 
 
In conclusion, molecular contrast-enhanced ultrasound is well established as a method for 
functional studies of diseases involving vascular pathology. This has been demonstrated in cancer, 
where imaging of angiogenic markers with targeted microbubbles have been evaluated both for 
diagnostic imaging and for monitoring response to antiangiogenic treatment. Progress in ligand and 
conjugation chemistry has led to the development of contrast agents with clinically desirable 
properties, and clinical trials have been initiated. Future optimization of ligands and microbubbles may 
lead to contrast agents that are valuable in management of cancer. We believe that identification of 
applications which utilize the inherent strengths of ultrasound imaging will be crucial for the 
introduction of molecular contrast-enhanced ultrasound in the clinic. 
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